Xenon files its seizure-drug application while pausing new psychiatry enrollment

Xenon ($XENE) submitted a US new-drug application for azetukalner to treat focal seizures, supported by its X-TOLE and X-TOLE2 studies and more than 1,500 patient-years of exposure. Submission is an application milestone, not confirmation that the FDA has accepted the filing or approved the medicine.

Separately, Xenon voluntarily paused new enrollment in its depression and bipolar programs after neuropsychiatric adverse events. Patients already enrolled can continue, and the epilepsy studies are not affected. The company is reviewing potential dosing changes with its monitoring advisers. It still expects first-quarter 2027 results from X-NOVA2, but the new enrollment pause introduces a separate development risk. The positive filing news should therefore not obscure the psychiatry-program safety update.

Sources:

• Xenon — NDA submission and psychiatry-program update, company release reprint